Are Mounjaro Jabs Safe? Mass Rollout Of Weight Loss Drug To Start In UK
For the first time, general practitioners (GPs) across the United Kingdom will be allowed to give prescriptions for a popular weight loss injection - Mounjaro, or tirzepatide. The drug, sometimes referred to as "skinny jabs", is an anti-diabetic drug made by the US-based pharmaceutical company Eli Lilly. The company said that the drug saw a "positive" response in India.
The UK's National Health Service (NHS) to monitor the mass rollout that will see around 220,000 people with the "greatest need" receive the weight loss jabs over the next three years. So far, people have been able to access the drug through a special weight loss service. Now, GPs can prescribe it to severely obese people and those who are suffering from other health problems.
How does Mounjaro work?
It slows down the process of food digestion and also lowers blood sugar, similar to other weight loss drugs like Ozempic, Wegovy and Rybelsus. Mounjaro is used to manage type 2 diabetes and aid in weight loss. Its active ingredient, tirzepatide, works by activating two hormone receptors in the gut: GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide). This dual mechanism helps regulate blood sugar levels and appetite.
What are the potential side effects of Mounjaro?
Nausea
Vomiting
Diarrhea
Digestive discomfort
Injection site irritation
Earlier this month, the UK government said that women taking popular medicines for weight loss and diabetes are being reminded to use "effective contraception" while taking these medicines.
Dr Alison Cave, MHRA Chief Safety Officer, said, "Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments. They are not a quick fix to lose weight and have not been assessed to be safe when used in this way."
"Our guidance offers patients a "one stop shop" for our up-to-date advice on how to use these powerful medicines safely," Cave added.
Mounjaro's positive response in India
The US-based pharmaceutical company said that the drug saw a "positive" response in India and beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India.
Data from research firm PharmaTrac revealed that Mounjaro has sold more than 81,570 units in India, totalling about 239.4 million rupees ($2.76 million) as of May. The drug logged a 60% rise in overall sales between April and May.
"Since 2020, Lilly has invested over $50 billion to increase production capacity (for global supply). We remain fully committed to meeting the demand for our medicines across the country," the company said recently.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
6 hours ago
- Time of India
Award for city doc
Lucknow-based physician Dr Pulkit Mehrotra will be honoured with the Young Investigator Award at the World Congress of Gastroenterology 2025, to be held as part of Australia Gastroenterology Week. Tired of too many ads? go ad free now A resident doctor at Sri Ramachandra Medical College, Chennai, Dr Pulkit's research, which explores overlooked liver disease in high-risk populations, was chosen from hundreds of international submissions. "It's a big moment for me and my mentors," said Dr Mehrotra.
New Indian Express
7 hours ago
- New Indian Express
Israel bombs residential block in Gaza City killing at least 20, including 9 children; over 81 killed in Gaza today
Israel on Saturday bombed a heavily populated residential block in Gaza City's al-Tuffah neighbourhood killing at least 20 Palestinians, including nine children. According to Gaza's Health Ministry, at least 81 Palestinains were killed on Saturday in various attacks across Gaza, including those near the aid distribution sites of the US-backed and Israeli military-operated Gaza Human Rights Foundation (GHF). Rights groups and the UN have refused to cooperate with the GHF, slamming it as a "death trap" for Palestinians and accusing it of aiding Israel in its genocidal war on Gaza. According to Gaza's health ministry, Israel has killed more than 549 Palestinians at aid distribution sites since the GHF began operations last month. The UN agency for Palestinian refugees, UNRWA, called the GHF an "abomination" that has put Palestinians' lives at risk, while a spokesman for the UN human rights office, Thameen Al-Kheetan, condemned the "weaponisation of food" in the territory. Meanwhile, Qatar on Saturday said that it and fellow mediators --the United States and Egypt-- were engaging with Israel and Hamas to build on momentum from the ceasefire with Iran and work towards a Gaza truce. "If we don't utilise this window of opportunity and this momentum, it's an opportunity lost amongst many in the near past. We don't want to see that again," said Qatar's foreign ministry spokesman Majed al-Ansari. According to Gaza's Health Ministry, Israel has so far killed at least 56,412 Palestinians in Gaza with more than half being women and children. Israel has also targeted and killed hundreds of journalists, health care workers and aid workers. Israel has also targeted hospitals, refugee camps, schools and residential complexes, causing mass casualties of civilians, mostly children. However, Israeli newspaper Haaretz on Friday reported the death toll to be far higher at around 100,000, which is about 4% of Gaza's entire population. The report said that in addition to the deaths from Israeli attacks, many Palestinians have lost their lives from the indirect effects of the genocidal war, such as hunger, cold and diseases amid Israel's blockade of humanitarian assistance and targeting of Gaza's health system.
Time of India
7 hours ago
- Time of India
Lawyer duo from Kerala earns recognition for anti-drug awareness campaign during pan-India road trip
Kochi: When Kochi-based lawyers Binu Varghese, 58, and Nijas Thamarassery, 28, set out on a mission to travel across India spreading awareness against drug abuse, they had no idea their initiative would carve a place in Worldwide Book of Records. Tired of too many ads? go ad free now What began as a grassroots effort to combat rising drug abuse in their own neighbourhoods evolved into Bharath Darshan Yatra — a two-phase road trip that spanned international borders, stirred public dialogue and touched countless young lives. Driven by a shared concern over increasing drug-related incidents in Kerala, the duo began their odyssey with Himalayan Challenge from Aug 16 to Sept 8, 2023. In 24 days, they traversed 9,145km across high-altitude terrain and harsh weather. The second phase, Northeastern Challenge, lasted from March 2 to April 27, 2025, covering 14,196km in 56 days through India's northeastern states and remote border regions adjoining Myanmar, Nepal, Bhutan, Tibet and Bangladesh. What makes their journey more than just a record-breaking feat is its purpose. They engaged directly with schools, youth groups and local communities along their route, delivering awareness sessions using modules approved by narcotics control bureau. "In most places, local organizations and educational institutions eagerly joined hands with us to take our message to young minds," said Nijas. Their travel unearthed disturbing insights into drug use patterns in various states. In Nagaland, for instance, they discovered widespread use of substances not yet listed under NDPS Act, making legal intervention difficult. "We found that enforcement is affected not because of inaction, but because of legislative gaps," Varghese noted. Tired of too many ads? go ad free now Despite facing criticism and scepticism early on, their recognition by Worldwide Book of Records validated their efforts. They say their journey isn't over but only evolving into a continued campaign to build a drug-aware and resilient society.
